Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
Stay updated with breaking news from History Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
Sự kiện 'Câu chuyện Du học tại Mỹ' giải đáp những thắc về tình hình nhập học các trường ở từng tiểu bang, cách hòa nhập khi học tại nước ngoài. - VnExpress
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial Highlights: Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity’s plan to target early stage MSA patients. Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA. Agreement that ATH434 has potential as a disease modifying treatment. MELBOURNE, Australia and SAN FRANCISCO, June 23, 2021 /PRNewswire...
Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTSTAND) velocity, and confirm safety and tolerability benefits of vamorolone over the 2.5-year follow u...